Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04028765 · ClinicalTrials.gov registry record · Phase 4

Pitocin or Oral Misoprostol for PROM IOL

A Phase 4 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 4
Development phase
108
Enrollment target

NCT04028765: Completed Phase 4 study, sponsored by University of Pennsylvania.

NCT04028765 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 108 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04028765, a Phase 4 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 4
Development phase
108 participants
Enrollment target

Study Summary

Premature rupture of membranes (PROM) is a common occurrence of pregnancies at term. A delay from PROM to labor is associated with an increased risk of intrauterine infection and associated maternal and fetal morbidity; therefore, induction of labor (IOL) is recommended. The ideal agent for IOL is not known, particularly among specific subpopulations. The primary aim of this study is to determine if oxytocin (Pitocin) or oral misoprostol results in a shorter interval to delivery after the start of induction among nulliparous women with unfavorable cervical exams with term PROM.

Primary Outcome

Time (hours) from start of IOL (As defined by receipt of first medication for induction of labor) to delivery of infant.

Interventions

  • DRUG Oxytocin
  • DRUG Misoprostol

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2019-08-12
Est. Completion 2023-01-08
Phase Phase 4
University of Pennsylvania

1,423 total trials

What the finished NCT04028765 record still lists

NCT04028765 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.

NCT04028765 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04028765 about?

NCT04028765 is a clinical study titled "Pitocin or Oral Misoprostol for PROM IOL". Premature rupture of membranes (PROM) is a common occurrence of pregnancies at term. A delay from PROM to labor is associated with an increased risk of intrauterine infection and associated maternal and fetal morbidity; therefore, induction of labor (IOL) is recommended. The ideal agent for IOL is n...

What is the current status of trial NCT04028765?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2019-08-12. Estimated completion is 2023-01-08.

What interventions are being tested in trial NCT04028765?

The interventions under investigation include: Oxytocin (DRUG), Misoprostol (DRUG).

Who is sponsoring clinical trial NCT04028765?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04028765's enrollment target sits among peer trials

108 740th of 2000 higher than 1,256 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02703207 · 108 participants · NA

    Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

  • NCT02744677 · 108 participants · NA

    COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

  • NCT02781883 · 108 participants · Phase 2

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  • NCT03848663 · 108 participants · NA

    Visual Remapping to Aid Reading With Field Loss

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04028765, the US trial registry maintained by the National Library of Medicine. NCT04028765 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.